Hims & Hers Health stock fell as much as 5% early Tuesday after the company reported revenue late Monday that fell shy of ...

Hims & Hers delivered strong Q2 growth, driven by compounded GLP-1 offerings, but faces uncertainty as regulatory and supply ...

Novo Nordisk A/V (NYSE: NVO) stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is ...

At least 26 patients have filed lawsuits in Marion County against Eli Lilly and Co. over its marketing of GLP-1 drugs ...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...

Novo Nordisk is scheduled to report results for the second quarter on Wednesday. Here is what you need to know: PROFIT FORECAST: The company pre-released preliminary second-quarter numbers last week, ...

Ozempic Market The Ozempic market is set for explosive growth, with a forecasted 10.1% CAGR to reach USD 58.4 billion by 2035. A ro ...

SAP opened its new campus in Bengaluru on Tuesday, marking it as the company’s second-largest R&D hub outside its ...

Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss ...

Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported ...

UBS has lowered its rating on Novo Nordisk (NYSE:NVO) from 'buy' to 'neutral', slashing the price target to DKK340 from ...

This maker of weight-loss drugs saw its share price zoom and then crash. The CEO has been replaced. The incoming boss will ...